Röltgen's research "Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination"; what a catastrophic HOT MESS! DISASTER

Immune imprinting, breadth of variant recognition and germinal center response in human SARS-CoV-2 infection and vaccination Cell. Published: January 24, 2022DOI:https://doi.org/10.1016/j.cell.2022.01.018

Key findings:

• Vaccination confers broader IgG binding of variant RBDs than SARS-CoV-2 infection

• Imprinting from initial antigen exposures alters IgG responses to viral variants

• Histology of mRNA vaccinee lymph nodes shows abundant germinal centers

• Vaccine spike antigen and mRNA persist for weeks in lymph node germinal centers

A key summary statement:

“In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks post-vaccination in some cases. SARS-CoV-2 antibody specificity, breadth and maturation are affected by imprinting from exposure history, and distinct histological and antigenic contexts in infection compared to vaccination.”

There is clear Original antigenic sin playing a role.

Key finding:

i) The belief that was pushed on the globe’s population was that as part of the response to the vaccine inducing spike protein production, that the body itself e.g. enzymes like RNAases etc. would eliminate the LNP content, the mRNA itself as well as spike. But people like McCullough, Patterson, and myself were clamoring that there was indication of nucleoside molecular caps placed on the 5 and 3 prime ends of the mRNA strands that was there to stabilize it and this allowed it potentially to churn out multiple spike and not only for a ‘one off’ use. Not for only single use.

This CELL publication raises a serious issue with this paragraph and shows that spike and antigen is present for up to 60 days post 2nd vaccine. This means that the body does not destroy the vaccine content e.g. genetic material etc. as we were told by vaccine developers and all involved. It was all a lie and this has huge implications.

“Prolonged detection of vaccine mRNA in LN GCs, and spike antigen in LN GCs and blood  following SARS-CoV-2 mRNA vaccination

The biodistribution, quantity and persistence of vaccine mRNA and spike antigen after vaccination (with the Pfizer vaccine), and viral antigens after SARS-CoV-2 infection, are incompletely understood but are likely to be major determinants of immune responses. We performed in situ hybridization with control and SARS-CoV-2 vaccine mRNA-specific RNAScope probes in the core needle biopsies of the ipsilateral axillary LNs that were collected 7-60 days after 2nd dose of mRNA-1273 or BNT162b2 vaccination, and detected vaccine mRNA collected in the GCs of LNs on day 7, 16, and 37 post vaccination, with lower but still appreciable specific signal at day 60 (Figures 7A -7E). Only rare foci of vaccine mRNA were seen outside of GCs. Axillary LN core needle biopsie of non-vaccinees (n = 3) and COVID-19 patient specimens were negative for vaccine probe hybridization. Immunohistochemical staining for spike antigen in mRNA vaccinated patient LNs varied between individuals, but showed abundant spike protein in GCs 16 days post-2nd dose, with spike antigen still present as late as 60 days post-2nd dose. Spike antigen localized in a reticular pattern around the GC cells, similar to staining for follicular dendritic cell processes (Figure 7B). COVID-19 patient LNs showed lower quantities of spike antigen, but a rare GC had positive staining (Figure 7F). Immunohistochemical staining for N antigen in peribronchial LN secondary and primary follicles of COVID-19 patients (Figures 7F - 7I) was positive in 5 of the 7 patients, with a mean percentage of nucleocapsid-positive follicles of more than 25%.

We find that BNT162b2 vaccination produces IgG responses to spike and RBD at concentrations as  high as those of severely ill COVID-19 patients and follows a similar time course. Unlike infection, which stimulates robust but short-lived IgM and IgA responses, vaccination shows a pronounced bias for IgG production even at early time point…’

ii) There is also heavy OAS as there is heavy Ab response to the original initial strain and not the prevailing variant.

iii) ‘At least some portion of spike antigen generated after administration of BNT162b2 becomes distributed into the blood. We detected spike antigen in 96% of vaccinees in plasma collected one to two days after the prime injection, with antigen levels reaching as high as 174 pg/mL. The range of spike antigen concentrations in the blood of vaccinees at this early time point largely overlaps with the range of spike antigen concentrations reported in plasma in a study of acute infection (Ogata et al., 2020), although a small number of infected individuals had higher concentrations in the ng/mL range.’

This is a critical finding. I have long argued with Wheelan, McCullough, Bhakdi, Yeadon, Malone etc. that it appears that the spike itself is becoming untethered from the molecular glue (transmembrane) and entering the blood stream. We are unsure how. Ogata showed that in the HCWs where spike was detected soon after vaccination in the blood stream as we as up to 2 weeks and I think as much as one month post vaccine. This mirrored the Japanese biodistribution data FOIA request that showed that the LNP and content was bio-accumulating at the ovaries, testes, spleen, ovaries, adrenals etc. in the rat model. This was the watershed moment that showed us spike was entering the blood stream and not staying localized to the deltoid, shoulder area as was assured. Not just Abs, but spike was entering the blood and has been devastating the vascular endothelium.

iv) to add to this, Bruce Patterson and his group have found spike and components at 15 months in the blood stream post infection and we, myself included, argue that we can extrapolate to the vaccine and that spike would be found in the blood at 15 months. A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection. They found the S1 sub-unit.

Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) Up to 15 Months Post-Infection

The implications of this is huge and can be catastrophic long term. We did not study this and again, a devastating failure of the vaccine developers and FDA in ensuring this was looked at. This may indeed explain the long COVID symptoms that are reported as spike is biologically active for over one year post shot. If it is for infection as per Patterson, it will near 100% be for vaccine and maybe at even higher levels.